BioVaxys to Showcase Innovations in Cancer Treatment
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) is thrilled to announce its upcoming presentation at a prominent conference dedicated to personalized cancer vaccines. The event will feature a presentation titled "A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies." This summit serves as a crucial meeting point for leading industry professionals focused on advancing personalized cancer vaccination strategies.
Overview of the Personalized Cancer Vaccine Summit
The Personalized Cancer Vaccine Summit brings together top experts and organizations to discuss the latest breakthroughs in the field. Attendees will focus on enhancing mRNA, DNA, and peptide vaccines, integrating them with immune-checkpoint inhibitors to more effectively target tumor pathways while minimizing unnecessary side effects. Notable companies such as BioNTec, CureVac, and The Mayo Clinic will also share their insights, making this an excellent networking opportunity.
BioVaxys' Role in Cancer Immunotherapy
At the summit, Dr. David Berd, Chief Medical Officer at BioVaxys, will present groundbreaking data from recent in vivo studies involving DPX. This research has been conducted by distinguished colleagues, including Dr. Pramrod K. Srivastava and Dr. Hakimeh Ebrahimi-Nik, who are both making significant contributions to the field of cancer immunology at their respective institutions.
Company Insights and Future Directions
Kenneth Kovan, President and Chief Operating Officer of BioVaxys, highlighted the importance of the upcoming conference. While specific details regarding new therapeutic roles for DPX and neoepitopes will be kept exclusive to conference attendees, preliminary data suggests that DPX could play a pivotal role in the development of tumor vaccines that elicit effective tumor rejection responses.
Progressing Research on DPX Technology
BioVaxys is deeply engaged in extensive research alongside Dr. Nik and her team to investigate DPX's potential in delivering effective tumor neoepitope vaccines. This ongoing research aims to validate DPX's ability to induce strong anti-tumor immune responses.
About BioVaxys Technology Corp.
Based in British Columbia, Canada, BioVaxys Technology Corp. is committed to improving patient health through its innovative immunotherapy platforms, including the DPX™ immune-educating technology. This approach seeks to enhance treatment outcomes for various conditions, including cancers and infectious diseases. The company's clinical pipeline features several promising candidates, such as maveropepimut-S (MVP-S), which targets advanced cancers more effectively. MVP-S has demonstrated a favorable safety profile and clinical benefits across multiple cancer types.
Innovative Solutions Under Development
Current projects include DPX™+SurMAGE, which combines treatments for two different cancer antigens, along with other personalized immunotherapeutic vaccines. This variety in the pipeline underscores BioVaxys' commitment to addressing urgent medical needs, particularly in the field of oncology.
Contact BioVaxys
For inquiries, please contact us at:
Phone: +1 646 452 7054
Email: [email protected]
Frequently Asked Questions
What is BioVaxys Technology Corp. known for?
BioVaxys Technology Corp. specializes in creating innovative immunotherapies, especially through its DPX™ immune-educating platform.
When will BioVaxys present at the summit?
BioVaxys is scheduled to present its findings at the Personalized Cancer Vaccine Summit, taking place in early December.
What is the DPX platform?
DPX is a cutting-edge immune-educating technology designed to stimulate targeted and robust immune responses against cancer.
How does BioVaxys contribute to cancer research?
By utilizing advanced technologies, BioVaxys aims to develop more effective cancer treatments through personalized vaccines.
Where can I find more information about BioVaxys?
For updates and information about their research and developments, visit the official BioVaxys website or follow them on social media.
